The association between physician reimbursement in the US and use of hematopoietic colony stimulating factors as adjunct therapy for older patients with acute myeloid leukemia: Results from the 1997 American Society of Clinical Oncology survey

C. L. Bennett, M. R. Bishop, M. S. Tallman, M. R. Somerfield, J. Feinglass, Thomas J Smith

Research output: Contribution to journalArticle

Abstract

Background/objectives: Financial considerations play an important role in the delivery of medical care in the US. In 1996, revised guidelines from the American Society of Clinical Oncology (ASCO) indicated that granulocyte colony-stimulating factor (G-CSF) and granulocyte macrophage-colony stimulating factor (GM-CSF) were unlikely to be harmful for older acute myeloid leukemia (AML) patients and suggested that physicians could consider their use in this setting. In 1997, the ASCO health services research committee evaluated whether physician reimbursement was a primary determinant in the decision to use G-CSF and GM-CSF in this clinical situation. Patients and methods: A questionnaire describing clinical scenarios for a 67-year-old man with newly diagnosed de novo AML was mailed to 1500 ASCO members who practiced medical oncology and hematology. Physicians were queried about their preferences for adjunctive CSF use following induction and consolidation chemotherapy. Results: Of 1020 potentially eligible respondents, returned surveys were received from 672. Following induction chemotherapy, support for CSF use was 40%, similar in magnitude for that for non-use of these agents. The most important determinant of support for CSF use was being in a fee-for-service practice (P <0.001). Conclusions: Physicians in the US are mixed in their support for CSFs for older AML patients. Support was high in settings where CSF use was accompanied by financial profit to the physician practice, and support was low otherwise.

Original languageEnglish (US)
Pages (from-to)1355-1359
Number of pages5
JournalAnnals of Oncology
Volume10
Issue number11
DOIs
StatePublished - 1999
Externally publishedYes

Fingerprint

Colony-Stimulating Factors
Acute Myeloid Leukemia
Medical Oncology
Physicians
Induction Chemotherapy
Granulocyte Colony-Stimulating Factor
Granulocyte-Macrophage Colony-Stimulating Factor
Consolidation Chemotherapy
Therapeutics
Fee-for-Service Plans
Health Services Research
Hematology
Surveys and Questionnaires
Guidelines

Keywords

  • Costs
  • Fee-for-service
  • Granulocyte colony stimulating factors
  • Granulocyte macrophage colony stimulating factors
  • Hematopoietic colony stimulating factors
  • HMO

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{f5731c416f3d48b1af543f917db42266,
title = "The association between physician reimbursement in the US and use of hematopoietic colony stimulating factors as adjunct therapy for older patients with acute myeloid leukemia: Results from the 1997 American Society of Clinical Oncology survey",
abstract = "Background/objectives: Financial considerations play an important role in the delivery of medical care in the US. In 1996, revised guidelines from the American Society of Clinical Oncology (ASCO) indicated that granulocyte colony-stimulating factor (G-CSF) and granulocyte macrophage-colony stimulating factor (GM-CSF) were unlikely to be harmful for older acute myeloid leukemia (AML) patients and suggested that physicians could consider their use in this setting. In 1997, the ASCO health services research committee evaluated whether physician reimbursement was a primary determinant in the decision to use G-CSF and GM-CSF in this clinical situation. Patients and methods: A questionnaire describing clinical scenarios for a 67-year-old man with newly diagnosed de novo AML was mailed to 1500 ASCO members who practiced medical oncology and hematology. Physicians were queried about their preferences for adjunctive CSF use following induction and consolidation chemotherapy. Results: Of 1020 potentially eligible respondents, returned surveys were received from 672. Following induction chemotherapy, support for CSF use was 40{\%}, similar in magnitude for that for non-use of these agents. The most important determinant of support for CSF use was being in a fee-for-service practice (P <0.001). Conclusions: Physicians in the US are mixed in their support for CSFs for older AML patients. Support was high in settings where CSF use was accompanied by financial profit to the physician practice, and support was low otherwise.",
keywords = "Costs, Fee-for-service, Granulocyte colony stimulating factors, Granulocyte macrophage colony stimulating factors, Hematopoietic colony stimulating factors, HMO",
author = "Bennett, {C. L.} and Bishop, {M. R.} and Tallman, {M. S.} and Somerfield, {M. R.} and J. Feinglass and Smith, {Thomas J}",
year = "1999",
doi = "10.1023/A:1008353130228",
language = "English (US)",
volume = "10",
pages = "1355--1359",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - The association between physician reimbursement in the US and use of hematopoietic colony stimulating factors as adjunct therapy for older patients with acute myeloid leukemia

T2 - Results from the 1997 American Society of Clinical Oncology survey

AU - Bennett, C. L.

AU - Bishop, M. R.

AU - Tallman, M. S.

AU - Somerfield, M. R.

AU - Feinglass, J.

AU - Smith, Thomas J

PY - 1999

Y1 - 1999

N2 - Background/objectives: Financial considerations play an important role in the delivery of medical care in the US. In 1996, revised guidelines from the American Society of Clinical Oncology (ASCO) indicated that granulocyte colony-stimulating factor (G-CSF) and granulocyte macrophage-colony stimulating factor (GM-CSF) were unlikely to be harmful for older acute myeloid leukemia (AML) patients and suggested that physicians could consider their use in this setting. In 1997, the ASCO health services research committee evaluated whether physician reimbursement was a primary determinant in the decision to use G-CSF and GM-CSF in this clinical situation. Patients and methods: A questionnaire describing clinical scenarios for a 67-year-old man with newly diagnosed de novo AML was mailed to 1500 ASCO members who practiced medical oncology and hematology. Physicians were queried about their preferences for adjunctive CSF use following induction and consolidation chemotherapy. Results: Of 1020 potentially eligible respondents, returned surveys were received from 672. Following induction chemotherapy, support for CSF use was 40%, similar in magnitude for that for non-use of these agents. The most important determinant of support for CSF use was being in a fee-for-service practice (P <0.001). Conclusions: Physicians in the US are mixed in their support for CSFs for older AML patients. Support was high in settings where CSF use was accompanied by financial profit to the physician practice, and support was low otherwise.

AB - Background/objectives: Financial considerations play an important role in the delivery of medical care in the US. In 1996, revised guidelines from the American Society of Clinical Oncology (ASCO) indicated that granulocyte colony-stimulating factor (G-CSF) and granulocyte macrophage-colony stimulating factor (GM-CSF) were unlikely to be harmful for older acute myeloid leukemia (AML) patients and suggested that physicians could consider their use in this setting. In 1997, the ASCO health services research committee evaluated whether physician reimbursement was a primary determinant in the decision to use G-CSF and GM-CSF in this clinical situation. Patients and methods: A questionnaire describing clinical scenarios for a 67-year-old man with newly diagnosed de novo AML was mailed to 1500 ASCO members who practiced medical oncology and hematology. Physicians were queried about their preferences for adjunctive CSF use following induction and consolidation chemotherapy. Results: Of 1020 potentially eligible respondents, returned surveys were received from 672. Following induction chemotherapy, support for CSF use was 40%, similar in magnitude for that for non-use of these agents. The most important determinant of support for CSF use was being in a fee-for-service practice (P <0.001). Conclusions: Physicians in the US are mixed in their support for CSFs for older AML patients. Support was high in settings where CSF use was accompanied by financial profit to the physician practice, and support was low otherwise.

KW - Costs

KW - Fee-for-service

KW - Granulocyte colony stimulating factors

KW - Granulocyte macrophage colony stimulating factors

KW - Hematopoietic colony stimulating factors

KW - HMO

UR - http://www.scopus.com/inward/record.url?scp=0032762635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032762635&partnerID=8YFLogxK

U2 - 10.1023/A:1008353130228

DO - 10.1023/A:1008353130228

M3 - Article

C2 - 10631465

AN - SCOPUS:0032762635

VL - 10

SP - 1355

EP - 1359

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 11

ER -